Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study

被引：111

作者：

Fagerli, Karen Minde ^{[1
]}

Lie, Elisabeth ^{[1
]}

van der Heijde, Desiree ^{[1
,2
]}

Heiberg, Marte Schrumpf ^{[1
]}

Kalstad, Synove ^{[3
]}

Rodevand, Erik ^{[4
]}

Mikkelsen, Knut ^{[5
]}

Lexberg, Ase Stavland ^{[6
]}

Kvien, Tore K. ^{[1
]}

机构：

[1] Diakonhjemmet Hosp, Deprtment Rheumatol, N-0319 Oslo, Norway

[2] Leiden Univ Med Ctr, Dept Rheumatol, Leiden, Netherlands

[3] Univ Hosp Northern Norway, Dept Rheumatol, Tromso, Norway

[4] St Olavs Hosp, Depatment Rheumatol, Trondheim, Norway

[5] Lillehammer Hosp Rheumat Dis, Dept Rheumatol, Lillehammer, Norway

[6] Vestre Viken Drammen Hosp, Dept Rheumatol, Drammen, Norway

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2013年 / 72卷 / 11期

关键词：

Anti-TNF; Psoriatic Arthritis; Treatment; ANKYLOSING-SPONDYLITIS; RHEUMATOID-ARTHRITIS; BIOLOGICS; SAFETY; ADALIMUMAB; EFFICACY; ANTAGONISTS; ETANERCEPT; THERAPIES; REGISTER;

D O I：

10.1136/annrheumdis-2012-203018

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background Tumour necrosis factor inhibitors (TNFi) are efficacious in patients with psoriatic arthritis (PsA), but some patients do not respond or do not tolerate their first TNFi, and are switched to a different TNFi. Evidence supporting this practice is limited, and we wanted to investigate the effectiveness of switching to a second TNFi. Material and methods From a longitudinal observational study (LOS) we selected patients with PsA who were starting their first TNFi, and identified patients who had switched to a second TNFi (switchers'). Three-month responses and 3-year drug-survival were compared between switchers and non-switchers, and within switchers. Results Switchers (n=95) receiving their second TNFi had significantly poorer responses compared with non-switchers (n=344) (ACR50 response: 22.5% vs 40.0%, DAS28 remission: 28.2% vs 54.1%). There was a trend towards poorer responses to the second TNFi compared with the first TNFi within switchers. Estimated 3-year drug-survival was 36% for the second TNFi compared with 57% for the first TNFi overall. Conclusions 20-40% of patients had a response on a second TNFi after having failed one TNFi in this LOS. This observation highlights the need for treatments with other mechanisms of action than TNF inhibition in patients with PsA.

引用

页码：1840 / 1844

页数：5

共 20 条

[1] Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial [J].

Antoni, C ;

Krueger, GG ;

de Vlam, K ;

Birbara, C ;

Beutler, A ;

Guzzo, C ;

Zhou, B ;

Dooley, LT ;

Kavanaugh, A .

ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (08) :1150-1157

[2] The estimation of a preference-based measure of health from the SF-36 [J].

Brazier, J ;

Roberts, J ;

Deverill, M .

JOURNAL OF HEALTH ECONOMICS, 2002, 21 (02) :271-292

[3] Sustained response to long-term biologics and switching in psoriatic arthritis: results from real life experience [J].

Coates, L. C. ;

Cawkwell, L. S. ;

Ng, N. W. F. ;

Bennett, A. N. ;

Bryer, D. J. ;

Fraser, A. D. ;

Emery, P. ;

Marzo-Ortega, H. .

ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (05) :717-719

[4] Switching tumour necrosis factor α antagonists in patients with ankylosing spondylitis and psoriatic arthritis:: an observational study over a 5-year period [J].

Conti, Fabrizio ;

Ceccarelli, Fulvia ;

Marocchi, Elisa ;

Magrini, Leonardo ;

Spinelli, Francesca Romana ;

Spadaro, Antonio ;

Scrivo, Rossana ;

Valesini, Guido .

ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (10) :1393-1397

[5] AMERICAN-COLLEGE-OF-RHEUMATOLOGY PRELIMINARY DEFINITION OF IMPROVEMENT IN RHEUMATOID-ARTHRITIS [J].

FELSON, DT ;

ANDERSON, JJ ;

BOERS, M ;

BOMBARDIER, C ;

FURST, D ;

GOLDSMITH, C ;

KATZ, LM ;

LIGHTFOOT, R ;

PAULUS, H ;

STRAND, V ;

TUGWELL, P ;

WEINBLATT, M ;

WILLIAMS, HJ ;

WOLFE, F ;

KIESZAK, S .

ARTHRITIS AND RHEUMATISM, 1995, 38 (06) :727-735

[6] Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors [J].

Fransen, J. ;

Antoni, C. ;

Mease, P. J. ;

Uter, W. ;

Kavanaugh, A. ;

Kalden, J. R. ;

Van Riel, P. L. C. M. .

ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (10) :1373-1378

[7] Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period [J].

Gomez-Reino, JJ ;

Carmona, L .

ARTHRITIS RESEARCH & THERAPY, 2006, 8 (01)

[8] European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies [J].

Gossec, L. ;

Smolen, J. S. ;

Gaujoux-Viala, C. ;

Ash, Z. ;

Marzo-Ortega, H. ;

van der Heijde, D. ;

FitzGerald, O. ;

Aletaha, D. ;

Balint, P. ;

Boumpas, D. ;

Braun, J. ;

Breedveld, F. C. ;

Burmester, G. ;

Canete, J. D. ;

de Wit, M. ;

Dagfinrud, H. ;

de Vlam, K. ;

Dougados, M. ;

Helliwell, P. ;

Kavanaugh, A. ;

Kvien, T. K. ;

Landewe, R. ;

Luger, T. ;

Maccarone, M. ;

McGonagle, D. ;

McHugh, N. ;

McInnes, I. B. ;

Ritchlin, C. ;

Sieper, J. ;

Tak, P. P. ;

Valesini, G. ;

Vencovsky, J. ;

Winthrop, K. L. ;

Zink, A. ;

Emery, P. .

ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (01) :4-12

[9] Golimumab, a New Human Tumor Necrosis Factor α Antibody, Administered Every Four Weeks as a Subcutaneous Injection in Psoriatic Arthritis Twenty-Four-Week Efficacy and Safety Results of a Randomized, Placebo-Controlled Study [J].

Kavanaugh, Arthur ;

McInnes, Iain ;

Mease, Philip ;

Krueger, Gerald G. ;

Gladman, Dafna ;

Gomez-Reino, Juan ;

Papp, Kim ;

Zrubek, Julie ;

Mudivarthy, Surekha ;

Mack, Michael ;

Visvanathan, Sudha ;

Beutler, Anna .

ARTHRITIS AND RHEUMATISM, 2009, 60 (04) :976-986

[10] Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register [J].

Lie, E. ;

van der Heijde, D. ;

Uhlig, T. ;

Mikkelsen, K. ;

Rodevand, E. ;

Koldingsnes, W. ;

Kaufmann, C. ;

Kvien, T. K. .

ANNALS OF THE RHEUMATIC DISEASES, 2011, 70 (01) :157-163

← 1 2 →